HK1044896A1 - 治療hiv感染和與之有關的繼發感染的方法 - Google Patents
治療hiv感染和與之有關的繼發感染的方法Info
- Publication number
- HK1044896A1 HK1044896A1 HK02106517.9A HK02106517A HK1044896A1 HK 1044896 A1 HK1044896 A1 HK 1044896A1 HK 02106517 A HK02106517 A HK 02106517A HK 1044896 A1 HK1044896 A1 HK 1044896A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hiv infection
- treating hiv
- secondary infections
- related secondary
- infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84801397A | 1997-04-28 | 1997-04-28 | |
PCT/US1998/008357 WO1998048843A1 (en) | 1997-04-28 | 1998-04-28 | Method of treating hiv infection and related secondary infections thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1044896A1 true HK1044896A1 (zh) | 2002-11-08 |
Family
ID=25302109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK02106517.9A HK1044896A1 (zh) | 1997-04-28 | 2002-09-04 | 治療hiv感染和與之有關的繼發感染的方法 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1202750A4 (zh) |
AU (1) | AU754242B2 (zh) |
CA (1) | CA2259041A1 (zh) |
HK (1) | HK1044896A1 (zh) |
WO (1) | WO1998048843A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
EP1509235A1 (en) * | 2002-05-31 | 2005-03-02 | Klinikum der Universität Regensburg | Method for the protection of endothelial and epithelial cells during chemotherapy |
ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
EP1718150A1 (en) * | 2004-02-25 | 2006-11-08 | The Government of the United States of America, represented by the Secretary, Department of Health and Human Services | Methylation inhibitor compounds |
MX2007010754A (es) * | 2005-03-03 | 2007-11-07 | Gentium Spa | Defibrotide y/u oligodeoxiribonucleotidos para tratar tumores dependientes de angiogenesis. |
AU2007231651B2 (en) * | 2005-03-03 | 2011-09-15 | Gentium Spa | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
ITMI20050336A1 (it) * | 2005-03-03 | 2006-09-04 | Gentium Spa | Formulazione ad attivita' anti-tumorale |
ES2694239T3 (es) | 2010-11-12 | 2018-12-19 | Gentium S.R.L. | Defibrótido para su uso en profilaxis y/o tratamiento de la enfermedad de Injerto contra huésped (GVHD) |
CA2874960C (en) | 2012-06-22 | 2021-05-18 | Gentium S.P.A. | Euglobulin-based method for determining the biological activity of defibrotide |
EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
IT1170215B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta |
IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
CA2082044C (en) * | 1990-05-04 | 1999-08-24 | David J. Ecker | Modulation of gene expression through interference with rna secondary structure |
IT1252174B (it) * | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
AU692433B2 (en) * | 1993-01-13 | 1998-06-11 | Arsinur Burcoglu | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
AU7516494A (en) * | 1993-07-29 | 1995-02-28 | Isis Pharmaceuticals, Inc. | Oligomers for modulating human immunodeficiency virus |
-
1998
- 1998-04-28 EP EP98918740A patent/EP1202750A4/en not_active Withdrawn
- 1998-04-28 WO PCT/US1998/008357 patent/WO1998048843A1/en not_active Application Discontinuation
- 1998-04-28 CA CA002259041A patent/CA2259041A1/en not_active Abandoned
- 1998-04-28 AU AU71609/98A patent/AU754242B2/en not_active Ceased
-
2002
- 2002-09-04 HK HK02106517.9A patent/HK1044896A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2259041A1 (en) | 1998-11-05 |
EP1202750A4 (en) | 2002-10-16 |
WO1998048843A1 (en) | 1998-11-05 |
EP1202750A1 (en) | 2002-05-08 |
AU754242B2 (en) | 2002-11-07 |
AU7160998A (en) | 1998-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL129352A0 (en) | Benzimidazole-2- carbamates for the treatment of viral infections and cancer | |
EP0831873A4 (en) | COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS | |
HK1023371A1 (en) | Compositions and methods for treating viral infections | |
PL335160A1 (en) | Treatment of hiv and carcinoma | |
EP0758242A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CYTOMEGALOVIRUS (CMV) INFECTIONS | |
AU8452698A (en) | Industrial fabrics and method of treatment | |
HK1044896A1 (zh) | 治療hiv感染和與之有關的繼發感染的方法 | |
EP0569703A3 (en) | Method of treatment and prevention of viral infections using HBNF and protein MK. | |
EP0975654A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTIONS | |
PL312908A1 (en) | Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors | |
GB9304746D0 (en) | Treatment of viral infections | |
EP0921803A4 (en) | METHOD FOR PREVENTING AND TREATING PESTVIRUS INFECTIONS AND RELATED DISEASES | |
ZA9510108B (en) | Composition and method for prevention and treatment of HIV-1 infection | |
AU4602897A (en) | Method for treatment of immunodeficiency virus infection | |
IL116925A (en) | Combinations of compounds useful for treating HIV infections and pharmaceutical compositions comprising these combinations | |
ZA972722B (en) | Method for prevention and treatment of viral infectious diseases. | |
EP0789565A4 (en) | PREVENTION OF HIV INFECTION | |
AU2473695A (en) | Method of slowing the progression of hiv infection | |
PL317876A1 (en) | Combined treatment of hiv infections | |
AU3530395A (en) | Treatment of viral infections | |
AU3553195A (en) | Methods of identifying agents which block hiv infection | |
AU6605196A (en) | Method of treating hepatitis delta virus infection | |
AU5085693A (en) | Method of treating epstein-barr virus infection | |
AU2001288870A1 (en) | Antiviral compounds and method of treating viral infections | |
AU1389897A (en) | Use of chemokines for the treatment and prevention of hiv infection |